ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI CTEP Last Month

December 31, 2010

In Brief: Daniel Nixon Of Emory to Head Prevention Program; Henderson To Get Rosenthal Award

January 30, 1987

Upton Finds Work For Former Division, Program Directors

September 14, 1979

Plant-Based Diet Associated With Improved Survival

April 25, 2008

Mozobil Plus G-CSF Increases Rate Of Cell Mobilization

September 30, 2005

NCI’s Kramer Named Director, NIH Medical Applications Office.

June 16, 2000